MusclePharm logo

MSLP - MusclePharm Share Price

$0.65 -0.0  -0.0%

Last Trade - 26/02/21

Sector
Consumer Defensives
Size
Micro Cap
Market Cap £15.5m
Enterprise Value £19.1m
Revenue £47.9m
Position in Universe 5961st / 6715
Bullish
Bearish
Unlock MSLP Revenue
Momentum
Relative Strength (%)
1m -9.24%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -31.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
177.4 166.9 132.5 102.2 88.1 79.7 -14.8%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,MusclePharm Corp revenues decreased 21% to $49.3M. Netincome totaled $365K vs. loss of $15.5M. Revenues reflectUnited States (Country) segment decrease of 21% to $35.4M,international segment decrease of 20% to $13.9M. Net Incomereflects Advertising and promotion decrease of 83% to $362K(expense), Interest expense, related party decrease of 85%to $228K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

MSLP Revenue Unlock MSLP Revenue

Net Income

MSLP Net Income Unlock MSLP Revenue

Normalised EPS

MSLP Normalised EPS Unlock MSLP Revenue

PE Ratio Range

MSLP PE Ratio Range Unlock MSLP Revenue

Dividend Yield Range

MSLP Dividend Yield Range Unlock MSLP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
MSLP EPS Forecasts Unlock MSLP Revenue
Profile Summary

MusclePharm Corporation is a performance lifestyle company. The Company develops, manufactures, markets and distributes branded nutritional supplements. The Company offers a range of powders, capsules, tablets and gels. The Company's portfolio of brands targets various types of fitness enthusiasts, including professional, combat sport, weight training, bodybuilding, running, basketball, soccer, cross fit, golf, tennis, volleyball and other active lifestyle activities. The MusclePharm Sport Series includes supplements that cover the needs of athletes, including their workout needs. MusclePharm Hybrid Series products include Assault, Amino1 and Combat Protein Powder. FitMiss products are designed and formulated for the active woman's lifestyle utilizing ingredients that cover the range of busy women's needs, including weight loss, multi-vitamins, protein shakes, detox, skin care and pre-workout energy mixes. MusclePharm Core products include BCAA 3:1:2, CLA Core and Fish Oil.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated August 4, 2006
Public Since June 26, 2006
No. of Shareholders: n/a
No. of Employees: 45
Sector Consumer Defensives
Industry Food & Tobacco
Index
Exchange Pink Sheets on Nasdaq
Shares in Issue 33,130,039
Free Float (0.0%)
Eligible for
ISAs
SIPPs
MSLP Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for MSLP
Upcoming Events for MSLP
Frequently Asked Questions for MusclePharm
What is the MusclePharm share price?

As of 26/02/21, shares in MusclePharm are trading at $0.65, giving the company a market capitalisation of £15.5m. This share price information is delayed by 15 minutes.

How has the MusclePharm share price performed this year?

Shares in MusclePharm are currently trading at $0.65 and the price has moved by 0.364k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the MusclePharm price has moved by 0.254k% over the past year.

What are the analyst and broker recommendations for MusclePharm?

Of the analysts with advisory recommendations for MusclePharm, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for MusclePharm is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will MusclePharm next release its financial results?

MusclePharm is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the MusclePharm dividend yield?

MusclePharm does not currently pay a dividend.

Does MusclePharm pay a dividend?

MusclePharm does not currently pay a dividend.

When does MusclePharm next pay dividends?

MusclePharm does not currently pay a dividend.

How do I buy MusclePharm shares?

To buy shares in MusclePharm you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of MusclePharm?

Shares in MusclePharm are currently trading at $0.65, giving the company a market capitalisation of £15.5m.

Where are MusclePharm shares listed? Where are MusclePharm shares listed?

Here are the trading details for MusclePharm:

Country of listing: United States
Exchange: PNK
Ticker Symbol: MSLP
What kind of share is MusclePharm?

Based on an overall assessment of its quality, value and momentum, MusclePharm is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a MusclePharm share price forecast 2021?

Shares in MusclePharm are currently priced at $0.65. At that level they are trading at 0.154% discount to the analyst consensus target price of 0.00.

How can I tell whether the MusclePharm share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MusclePharm. Over the past six months, the relative strength of its shares against the market has been 0.323k%. At the current price of $0.65, shares in MusclePharm are trading at 0.134k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the MusclePharm PE Ratio?

We were not able to find PE ratio data for MusclePharm.

Who are the key directors of MusclePharm?

MusclePharm's management team is headed by:

Ryan Drexler - CHM
John Desmond - IND
Allen Sciarillo - CFO
Michael Heller - DRC
Who are the major shareholders of MusclePharm?

Here are the top five shareholders of MusclePharm based on the size of their shareholding:

Drexler (Ryan Charles) Individual Investor
Percentage owned: 55.47% (18.4m shares)
Boston Private Wealth LLC Investment Advisor
Percentage owned: 11.01% (3.65m shares)
White Winston Select Asset Funds, LLC Private Equity
Percentage owned: 11.01% (3.65m shares)
Wynnefield Capital, Inc. Hedge Fund
Percentage owned: 6.37% (2.11m shares)
Consac, L.L.C. Corporation
Percentage owned: 4.53% (1.50m shares)
Similar to MSLP
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.